Page last updated: 2024-10-27

fluorouracil and Fibrosis, Radiation

fluorouracil has been researched along with Fibrosis, Radiation in 16 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Pulmonary toxicity was prospectively evaluated within a randomized trial for breast cancer patients at high risk for relapse, who postoperatively received as adjuvant therapy either 9 cycles of tailored chemotherapy (20 patients) (cyclophosphamide, epirubicin, 5-fluorouracil [FEC]) or standard FEC x 3 followed by high-dose chemotherapy (cyclophosphamide, thiotepa, carboplatin [CTCb]) supported by peripheral blood stem cell transplantation (14 patients)."5.10Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. ( Bergh, J; Blomqvist, C; Hernberg, M; Keyriläinen, J; Maasilta, P; Virkkunen, P; Wiklund, T, 2002)
" We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy."3.71Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002)
"To evaluate the efficacy of late accelerated hyperfractionated conformal radiotherapy (LACF) combined with capecitabine on esophageal carcinoma."2.76[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. ( Feng, XZ; Han, JQ; Sheng, W, 2011)
"Forty-four patients with esophageal squamous cell carcinoma (ESCC) were randomized into two groups."2.73[Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer]. ( Chen, K; Gao, XS; Lin, Q; Qiao, XY; Wang, YD; Zhou, ZG, 2008)
"Locoregional treatment of inflammatory breast cancer (IBC) is crucial because local relapses may be highly symptomatic and are commonly associated with distant metastasis."1.38Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up. ( Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C, 2012)
"Radiation pneumonitis was retrospectively graded using the Radiation Therapy Oncology Group (RTOG) scale by an observer blinded to the PET radiotoxicity score."1.37Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis. ( Ball, DL; Binns, D; Ding, Z; Herschtal, A; Hicks, RJ; Hogg, A; Mac Manus, MP, 2011)
" Five cardiopulmonary toxic events of Grade 3 or greater were observed in 4 patients, Grade 5 heart failure and Grade 3 pericarditis in 1 patient, and Grade 3 myocardial infarction, Grade 3 radiation pneumonitis, and Grade 3 pleural effusion."1.35Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. ( Chin, K; Gomi, K; Ito, H; Kozuka, T; Matsuura, M; Morota, M; Oguchi, M; Yamashita, T, 2009)
"Thirty months after the right breast cancer treatment, Stage I left breast cancer was diagnosed."1.33A case of metachronous bilateral breast cancer with bilateral radiation pneumonitis after breast-conserving therapy. ( Araki, N; Hiraoka, M; Kawamura, S; Kodama, H; Mise, K; Mitsumori, M; Nagata, Y; Narabayashi, M; Oya, N; Sakamoto, T; Tachiiri, S; Yamauchi, C, 2006)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's9 (56.25)29.6817
2010's6 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Suh, YG1
Lee, IJ1
Koom, WS1
Cha, J1
Lee, JY1
Kim, SK1
Lee, CG1
Su, J1
Zhu, S1
Liu, Z1
Zhao, Y1
Song, C1
Lin, Q1
Gao, XS1
Qiao, XY1
Chen, K1
Wang, YD1
Zhou, ZG1
Morota, M1
Gomi, K1
Kozuka, T1
Chin, K1
Matsuura, M1
Oguchi, M1
Ito, H1
Yamashita, T1
Mac Manus, MP1
Ding, Z1
Hogg, A1
Herschtal, A1
Binns, D1
Ball, DL1
Hicks, RJ1
Bourgier, C1
Pessoa, EL1
Dunant, A1
Heymann, S1
Spielmann, M1
Uzan, C1
Mathieu, MC1
Arriagada, R1
Marsiglia, H1
Erven, K1
Weltens, C1
Nackaerts, K1
Fieuws, S1
Decramer, M1
Lievens, Y1
Sheng, W1
Feng, XZ1
Han, JQ1
Lind, PA2
Marks, LB2
Jamieson, TA1
Carter, DL1
Vredenburgh, JJ1
Folz, RJ1
Prosnitz, LR2
Yamashita, H1
Nakagawa, K1
Tago, M1
Igaki, H1
Nakamura, N1
Shiraishi, K1
Sasano, N1
Ohtomo, K1
Narabayashi, M1
Mitsumori, M1
Araki, N1
Yamauchi, C1
Kawamura, S1
Sakamoto, T1
Tachiiri, S1
Oya, N1
Nagata, Y1
Hiraoka, M1
Mise, K1
Kodama, H1
Wang, S1
Liao, Z1
Wei, X1
Liu, HH1
Tucker, SL1
Hu, C1
Ajani, JA1
Phan, A1
Swisher, SG1
Mohan, R1
Cox, JD1
Komaki, R1
Mah, K1
Keane, TJ1
Van Dyk, J1
Braban, LE1
Poon, PY1
Hao, Y1
Hardenbergh, PH1
Clough, R1
Fan, M1
Hollis, D1
Hernando, ML1
Lucas, D1
Piepgrass, A1
Hernberg, M1
Virkkunen, P1
Maasilta, P1
Keyriläinen, J1
Blomqvist, C1
Bergh, J1
Wiklund, T1
Koukourakis, MI1
Giatromanolaki, A1
Kouroussis, C1
Kakolyris, S1
Sivridis, E1
Frangiadaki, C1
Retalis, G1
Georgoulias, V1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma, an Open, Prospective, Single-arm Phase II Study[NCT04212598]Phase 240 participants (Anticipated)Interventional2020-08-03Recruiting
Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405]97 participants (Actual)Interventional2016-10-31Terminated (stopped due to Withdrawal of analysis study Partner.)
Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study[NCT00594477]Phase 1100 participants (Actual)Interventional2008-01-04Completed
Proton Therapy for Peripheral Lymph Nodes in Breast Cancer[NCT01365845]18 participants (Actual)Interventional2012-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Volume of Heart Receiving ≥ 5 Gray (Gy)/Cobalt Gray Equivalent (CGE)

A reduction of 50% in heart volume exposed to radiation doses ≥ 5 Gy/CGE was considered preferred outcome in this study plan. (NCT01365845)
Timeframe: 2 weeks prior to starting radiation therapy.

Intervention% of heart receiving >= 5 Gray (Gy) (Median)
Conventional Photon Plan34.7
3D-Proton/Conventional Plan or 3D-proton Only2.7

Reviews

1 review available for fluorouracil and Fibrosis, Radiation

ArticleYear
Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
    Cancer, 2002, Jun-01, Volume: 94, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Com

2002

Trials

4 trials available for fluorouracil and Fibrosis, Radiation

ArticleYear
[Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2008
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:9

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycyt

2011
Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: a prospective clinical study.
    International journal of radiation oncology, biology, physics, 1994, Feb-01, Volume: 28, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Combined Modality

1994
Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Admi

2002

Other Studies

11 other studies available for fluorouracil and Fibrosis, Radiation

ArticleYear
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C

2014
Target volume delineation for radical radiotherapy of early oesophageal carcinoma in elderly patients.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2017, Volume: 21, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam

2017
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
    International journal of radiation oncology, biology, physics, 2009, Sep-01, Volume: 75, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ

2009
Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
    International journal of radiation oncology, biology, physics, 2011, Aug-01, Volume: 80, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat

2011
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
    International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma

2012
Changes in pulmonary function up to 10 years after locoregional breast irradiation.
    International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe

2012
The experience of concurrent chemoradiation for Japanese patients with superficial esophageal squamous cell carcinoma: a retrospective study.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2005
A case of metachronous bilateral breast cancer with bilateral radiation pneumonitis after breast-conserving therapy.
    Breast cancer (Tokyo, Japan), 2006, Volume: 13, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy;

2006
Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Dose-Response Relationship

2008
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; F

2002
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; F

2002
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; F

2002
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; F

2002
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas

2002